2024

Submitting GDP to TFDA/MOHW

2023

ES135 clinical study for Carpal Tunnel Syndrome by Tri-Service General Hospital IRB.

Subsidiary SML merged into Eusol

2022

Development of EPS221 and EPS222 for psychiatric and cardiovascular diseases.

Corporate transformation adapting to new market trends.

2020

Completed a small-scale SM-1 clinical trial in the US.

2019

Wugu pilot plant passed TFDA/MOHW follow-up inspection for biologics APIs.

2018

Completion of one of the SM-1 phase 3 clinical trial in the US.

Approved by Taiwan OTC on Emerging Stock Market

ES135 multi-center phase 3 pivotal clinical trial in Spinal Cord Injury was initiated in Taiwan.

2017

Acquired 100% equity in subsidiary Sequential Medicine Ltd for developing SM-1 as sleeping aid.

2011

TFDA approved the TVGH “compassionate use” program to treat 100 SCI patients with Eusol's investigational drug “ES135”.

2010

Wugu plant expansion.

2009

Signed the “Cooperative R&D and Licensing implementation Contract” with Taipei Veterans General Hospital

2008

Eusol Wugu facility was certified by Taiwan Health Authority as a GMP pilot plant for manufacturing biological drug substance.

2007

Plant expanded and process development for GMP production

2006

Pilot plant was set up at Wugu district in New Taipei Industrial Park.

Eusol R&D Department was set up at Innovation Center of National Yang-Ming University.

2005

Eusol Biotech Co., Ltd. was established.